Skip to content

For pharma teams comparing product-profile choices

Test product-profile choices with the HCP audience that matters.

Before a pharma team commits to a positioning, message, or product-profile direction, it may need structured input from the HCPs the decision is meant to reach.

See how profiles become a study Book a demo

Start with the commercial decision

A concept test is useful when a defined choice is still open.

An HCP product-profile concept test can help compare reactions to defined alternatives—what appears more relevant, where trade-offs emerge, and which questions deserve further work.

01

Choose a direction

Which of two product profiles should receive further commercial development?

02

Understand trade-offs

Which benefit, risk, or convenience trade-offs appear more compelling to the HCP audience in scope?

03

Refine the next step

Which profile or message elements deserve refinement before a larger study or launch-planning decision?

The FDA's Target Product Profile guidance describes a TPP as a planning tool for product-development goals. A commercial HCP concept test is a separate market-research input that examines how a defined audience responds to selected profile alternatives.

Prepare the profile before testing

What should a TPP include for your indication?

A Target Product Profile is a planning document that connects a product idea to the decision it needs to support. Before an HCP concept test, it should make the concept understandable, show which attributes matter, and make uncertainty visible. There is no single universal format, so adapt the detail to the indication, product stage, audience, and decision.

  1. 01

    Decision and indication

    The decision, indication, or use case in scope.

  2. 02

    Target population and setting

    The intended population, care setting, geography, and stage of use.

  3. 03

    Unmet need and current practice

    The problem to address, current options, and open hypotheses.

  4. 04

    Product concept

    The proposed attributes, with unknowns left visibly open.

  5. 05

    Performance, safety, and tolerability

    The relevant endpoints or characteristics and their evidence status.

  6. 06

    Differentiation and trade-offs

    The fair comparator and trade-offs the study should explore.

  7. 07

    Evidence and missing information

    The source, locator, date, reviewer, and gaps for each claim.

Label evidence before you ask for a reaction

Keep these categories visibly separate in the working profile: source-backed fact, operator-confirmed input, hypothesis, assumption, and missing evidence. A blank or qualified field is more useful than a plausible-sounding claim.

Download the PDF guide See how the profile becomes a study

A connected path

From product profile to fieldwork-ready comparison.

01

Define the comparison

State the decision, target HCP audience, market, profile alternatives, and what a useful comparison would change.

02

Prepare stimuli

Use approved visual TPP profiles or other defined product-profile assets tied to the study context.

03

Configure exposure and questions

Set how each profile is shown, how order is controlled, and which fit, relevance, trade-off, or follow-up questions the comparison needs.

See the complete workflow

TPP example

Comparing two HCP product profiles.

An insights team is evaluating two profile directions for a specialty product. The study question is: “Which profile gives the target HCP audience the clearest reason to consider the product, and which trade-off needs refinement before the next commercial decision?”

TPP dimensions
Efficacy
Patient population
Dosing frequency
Route of administration
Mechanism of action

Product X

Efficacy: 12.6 months mPFS, 20 months mOS
Efficacy endpoints can be tested head-to-head, as PFS is in this example, or for importance, more like OS is here.
Patient population: Adults with newly diagnosed metastatic disease
Dosing frequency: Once daily
Dosing frequency can shape convenience, adherence, and the trade-offs respondents weigh.
Route of administration: Oral
Mechanism of action: Targeted pathway inhibitor
Mechanism of action helps distinguish what the profile claims to change and which clinical context it serves.

Product Y

Efficacy: 15 months mPFS, no OS available
Patient population: Adults with previously treated metastatic disease
Define the patient population whose needs and experience the profile is meant to address.
Dosing frequency: Every 3 weeks
Route of administration: Intravenous infusion
Route of administration can change the practical burden and context in which a product is considered.
Mechanism of action: Dual immune checkpoint blockade

Decision context

Turn HCP feedback into a clearer next decision.

Research-owned

Method and analysis

Sampling, questionnaire design, pretesting, programming QA, fieldwork quality, and interpretation require qualified research judgment.

Decision-ready

Audience and analysis

The study team defines the sample and analysis plan needed to make the comparison useful for the decision in scope.

Connected

Profile-to-study operations

NquiRx connects approved profile context, review, supported programming, fieldwork handoffs, and early outputs without replacing researchers or panel providers.

Read AAPOR's survey best practices or learn when quantitative primary research is useful.

Move from profile to study

Keep the profile, questionnaire, fieldwork plan, and decision connected.

NquiRx helps teams make HCP comparison work more reviewable while researchers retain methodology, approvals, and final interpretation.

Book a demo